Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative & Oncological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SIGMAR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SIGMAR1 Full-Length Membrane Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Conformation). | View SIGMAR1 Products |
| Stable Cell Line / Gene Delivery | SIGMAR1 Lentivirus Premade Particles (Full-length ORF) for stable cell line construction. Preserves ER conformation. | View SIGMAR1 Products |
| Benchmark Ab | Anti-SIGMAR1 Benchmark Antibody. Recombinant positive control for western blot and screening. | View SIGMAR1 Products |
| Validator | SIGMAR1 siRNA Set. Sequence-specific knockdown for assay specificity verification. | View SIGMAR1 Products |
| Selectivity Panel | TMEM97 (Sigma-2) Membrane Protein. Critical counter-screening target for subtype selectivity validation. | View TMEM97 Products |
| Binding Partner | ITPR1/IP3R Recombinant Protein. Validated SIGMAR1 interaction partner for co-binding studies. | View ITPR1 Products |
| Related Target | VDAC1. Mitochondrial tethering partner; essential for ER-mitochondria coupling assays. | View VDAC1 Products |
| Pathway Partner | GRP78/HSPA5. ER chaperone competitor; critical for occupancy assay development. | View HSPA5 Products |
| Related Target | BDNF. Synergistic neuroprotective pathway marker for agonist validation. | View BDNF Products |
Critical Assay Requirements & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ER Membrane Topology & Transmembrane Protein Folding | Lentivirus-delivered Stable Cell Lines expressing full-length SIGMAR1 with native ER retention signals; HEK293 expression preserves post-translational modifications and native intracellular conformation. |
| Sigma-1 vs Sigma-2 Receptor Subtype Cross-reactivity | Strictly purified TMEM97 (Sigma-2) ortholog proteins (>95% purity, mass spectrometry verified) for counter-screening; ensures selectivity data. |
| Intracellular Calcium Flux Indirect Measurement | Co-expression systems with ITPR1 available; validated for IP3R-SIGMAR1 coupling assays. |
| Compound Permeability (BBB) Requirements | Cell-based functional assays using lentivirus-transduced lines; mimics BBB penetration requirements for CNS indications. |
| Off-target Liability (GPCR panel) | High-purity antigen available for custom SPR screening; endotoxin controlled (<1 EU/ug). |
| Lack of Reliable Controls for Assay Validation | Benchmark recombinant antibodies (Anti-SIGMAR1) and validated siRNA sets included for positive/negative assay validation. |
| False Positives in Functional Assays | Target-specific validated siRNA included for rigorous specificity checks; benchmark controls available. |
Live SIGMAR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The SIGMAR1 (Sigma-1 Receptor) therapeutic landscape is experiencing renewed investment following Phase 3 failures of traditional amyloid-targeting antibodies in Alzheimer's. As an intracellular chaperone localized to the ER-mitochondria interface, SIGMAR1 represents a non-traditional target for neurodegenerative diseases requiring novel assay paradigms. The race for SIGMAR1 therapeutics is intensifying, with major players shifting focus from pan-opioid ligands to selective agonists with chaperone-modulating properties. First-generation small molecules (Anavex 2-73 / Blarcamesine, Pridopidine) are in late-stage trials for Alzheimer's disease (also Rett Syndrome), Huntington's disease, and ALS (though Pridopidine faced setbacks in ALS). Concurrently, SIGMAR1 antagonists (e.g., ESTEVE's E-52862/S1RA) are gaining traction in neuropathic pain and oncology, while PROTAC degraders are emerging for glioblastoma and prostate cancer. The next wave of R&D is targeting highly selective, potent modulators with zero cross-reactivity to Sigma-2 receptor (TMEM97), as well as combination therapies with mitochondrial protectors and ER stress modulators for ALS and frontotemporal dementia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Anavex Life Sciences, Prilenia Therapeutics, Treeway | Alzheimer's, Huntington's, ALS, Rett Syndrome | ER Calcium Flux Assay (Need full-length membrane protein in native ER context via Lentivirus) |
| Small Molecule Antagonist | ESTEVE, Various Academic Labs | Neuropathic Pain, Solid Tumors | Selectivity Assay (Need Sequence Verified TMEM97/Sigma-2 controls) |
| Allosteric Modulator | Various Academic Institutes | Pain, Depression | Chaperone Competition Assay (Need GRP78/HSPA5 and ITPR1 for displacement studies) |
| Peptide/Protein Therapeutic | Emerging Biotech | Peripheral Neuropathy | Internalization Assay (Cell lines for ER targeting verification) |
| Gene Therapy | Preclinical Programs | ALS, Retinal Degeneration | Expression Validation (qPCR-validated lentiviral particles for transduction efficiency) |
| Targeted Protein Degradation (PROTAC) | Emerging Biotechs | Cancer (Glioblastoma, Prostate) | Degradation Tracking (Need high-purity intracellular target proteins) |
Key Mutations and Variants in SIGMAR1
Based on recent annotations, several mutations in SIGMAR1 have been associated with disease and drug response:
| Mutation | dbSNP ID | Clinical Significance | Evidence |
|---|---|---|---|
| Unknown | rs1800866 | Reported in UniProt (VAR_029750) | Functional studies needed |
| Unknown | rs140376902 | Uncertain significance; linked to HMNR2 | UniProt VAR_078816 |
| ALS16-associated mutation | Not specified | Decreases viability of motor neurons; mutant protein shows altered function | UniProt VAR_067311 |
These mutations underscore the need for mutant-specific assays and customized recombinant proteins for studying drug binding and resistance mechanisms.